Mesoblast (ASX:MSB), a global leader in allogeneic cellular therapies for inflammatory diseases, reported a 60% increase in Ryoncil (remestemcel-L-rknd) sales, generating US$35.1 million in gross revenue for the December 2025 quarter, up from the previous quarter.
Ryoncil, the first mesenchymal stromal cell therapy approved by the US Food and Drug Administration, remains the only FDA-approved treatment for children under 12 with steroid-refractory acute graft-versus-host disease.
The therapy is now set for evaluation in a pivotal trial as a second-line treatment for adults with SR-aGvHD, a market estimated to be three times the size of the pediatric segment.
The revenue growth strengthens Mesoblast’s balance sheet following a US$125 million five-year financing facility with its largest shareholder, which lowered the company’s cost of capital and enabled repayment of prior senior secured loans.
The facility also partially repaid a subordinated royalty obligation, which is expected to be fully cleared by mid-2026.
The new interest-only facility offers lower costs, flexibility in repayment, and does not encumber key assets or restrict licensing activities.
"Our strong balance sheet, continued growth in Ryoncil sales, and a lower-cost financing facility give us greater flexibility for strategic partnerships and label expansion," said CEO Dr. Silviu Itescu.